Pyxis Oncology (PYXS) Stock Price, News & Analysis

Company Overview

Pyxis Oncology, Inc. is a precision oncology company dedicated to advancing personalized cancer treatments through biomarker-driven insights. The company specializes in the discovery, development and commercialization of diagnostic assays that profile the tumor microenvironment and genomic alterations associated with immuno-oncology and targeted therapies. Utilizing proprietary ex vivo functional assays and next-generation sequencing platforms, Pyxis Oncology identifies determinants of drug response and resistance to inform clinical trial design and therapeutic strategies.

Pyxis Oncology’s product portfolio includes tissue-based and liquid biopsy assays designed to measure immune cell functionality, cytokine release and tumor-specific genetic mutations. Key services encompass functional immunoprofiling to evaluate patient response to immunotherapies, comprehensive genomic profiling to detect actionable mutations, and companion diagnostic development in collaboration with biopharmaceutical partners. The company’s integrated approach leverages high-throughput biomarker screening and data analytics to accelerate go-to-market timelines for novel oncology therapeutics.

Founded in 2020 and headquartered in the Boston metropolitan area, Pyxis Oncology operates state-of-the-art laboratories in North America and maintains partnerships across Europe and Asia to support global drug development programs. Leveraging a multidisciplinary team of immunologists, molecular biologists and bioinformaticians, the company aims to bridge the gap between laboratory research and clinical application, empowering oncologists with deeper insights into treatment mechanisms.

Under the leadership of CEO David J. Jung, M.D., M.B.A., and Chief Scientific Officer Audrey Kunzelmann, Ph.D., Pyxis Oncology has rapidly expanded its footprint in the oncology diagnostics space. The company is backed by a consortium of healthcare investors and collaborates with leading academic centers to validate its assays and drive innovation in precision immuno-oncology.

Key Stats

• Today's Range: $1.15 to $1.19
• 50-Day Range: $1.06 to $1.35
• 52-Week Range: $0.83 to $5.39
• Volume: 94,213 shs
• Average Volume: 727,845 shs
• Market Capitalization: $72.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Moderate Buy

Pyxis Oncology Stock Analysis - MarketRank™

Pyxis Oncology scored higher than 35% of companies evaluated by MarketBeat, and ranked 779th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Pyxis Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Pyxis Oncology has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Pyxis Oncology are expected to decrease in the coming year, from ($1.04) to ($1.29) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pyxis Oncology is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pyxis Oncology is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Pyxis Oncology has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.04% of the float of Pyxis Oncology has been sold short.

Short Interest Ratio / Days to Cover

Pyxis Oncology has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Pyxis Oncology has recently decreased by 4.48%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pyxis Oncology does not currently pay a dividend.

Dividend Growth

Pyxis Oncology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

14.04% of the float of Pyxis Oncology has been sold short.

Short Interest Ratio / Days to Cover

Pyxis Oncology has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Pyxis Oncology has recently decreased by 4.48%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.19

News Sentiment

Pyxis Oncology has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Pyxis Oncology this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for PYXS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pyxis Oncology insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.60% of the stock of Pyxis Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 39.09% of the stock of Pyxis Oncology is held by institutions.

PYXS Stock Analysis - Frequently Asked Questions

How have PYXS shares performed this year?

Pyxis Oncology's stock was trading at $1.56 at the start of the year. Since then, PYXS stock has decreased by 25.0% and is now trading at $1.17.

How were Pyxis Oncology's earnings last quarter?

Pyxis Oncology, Inc. (NASDAQ:PYXS) issued its quarterly earnings data on Thursday, May, 15th. The company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by $0.06.

When did Pyxis Oncology IPO?

Pyxis Oncology (PYXS) raised $158 million in an initial public offering (IPO) on Friday, October 8th 2021. The company issued 10,500,000 shares at $14.00-$16.00 per share.

Who are Pyxis Oncology's major shareholders?

Pyxis Oncology's top institutional shareholders include Kingstone Capital Partners Texas LLC (0.05%). Insiders that own company stock include Pfizer Inc, Lara Sullivan, Pamela Ann Connealy and Jitendra Wadhane.
View institutional ownership trends.

How do I buy shares of Pyxis Oncology?

Shares of PYXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Pyxis Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pyxis Oncology investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Walmart (WMT), Home Depot (HD) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/11/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PYXS
• CIK: 1782223
• Web: www.pyxisoncology.com
• Phone: 617-221-9059
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Pyxis Oncology: $9.00
• High Price Target: $13.00
• Low Price Target: $5.00
• Potential Upside/Downside: +669.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$77.33 million
• Net Margins: N/A
• Pretax Margin: -492.35%
• Return on Equity: -57.49%
• Return on Assets: -45.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.75
• Quick Ratio: 7.75

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.03 per share
• Price / Book: 0.58

Miscellaneous

• Outstanding Shares: 61,948,000
• Free Float: 55,382,000
• Market Cap: $72.48 million
• Optionable: Optionable
• Beta: 1.13